HGEN - Merck's Recent Acquisition Highlights OWS Funding Flowing Into COVID-19 Therapeutics
- Strong SACCOVID clinical trial results suggest an approval is forthcoming.
- Graft versus Host Disease linkage to the most promising therapeutics.
- Merck business model resonating with investors.
- Small pool of therapeutic drug companies represents ideal acquisition targets.
For further details see:
Merck's Recent Acquisition Highlights OWS Funding Flowing Into COVID-19 Therapeutics